<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112059</url>
  </required_header>
  <id_info>
    <org_study_id>F081024004</org_study_id>
    <nct_id>NCT01112059</nct_id>
  </id_info>
  <brief_title>Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients</brief_title>
  <acronym>DOXY</acronym>
  <official_title>A Randomized Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult CF Patients Hospitalized for Pulmonary Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the role of a well-known and well-tolerated
      antibiotic, doxycycline, in the treatment of cystic fibrosis patients who are hospitalized.
      This antibiotic does not effectively treat the bacteria in airways of cystic fibrosis
      patients, but may reduce the activity of inflammatory molecules in the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One molecule that is inhibited by doxycycline is matrix metalloprotease-9, which is emerging
      as an important mediator of lung inflammation and damage in cystic fibrosis. We hypothesize
      that the addition of treatment with doxycycline in CF inpatients will reduce MMP-9 activity
      and inflammatory markers in the sputum of cystic fibrosis patients compared to CF patients
      not treated with doxycycline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>1 month from enrollment</time_frame>
    <description>Examines tolerability and safety with focus on adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matrix Metalloprotease-9 (MMP-9) Protein Levels in Sputum</measure>
    <time_frame>8 days past baseline</time_frame>
    <description>Mean sputum matrix metalloprotease-9 (MMP-9) levels measured at the end of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Sputum Matrix Metalloprotease-9 (MMP-9) Activity End of Treatment</measure>
    <time_frame>8 days</time_frame>
    <description>Measurement of endogenous active matrix metalloprotease-9 (MMP-9) in the sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Pulmonary Function Over Treatment Duration</measure>
    <time_frame>Baseline to end of inpatient clinical exacerbation (average 14 days)</time_frame>
    <description>Observe change in FEV1% predicted from beginning to end of study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients given placebo twice a day for 8 days at beginning of inpatient CF exacerbation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients given doxycycline 100 mg tablet twice a day for 8 days at the beginning of inpatient CF exacerbation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>100 mg twice a day for 8 days</description>
    <arm_group_label>doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic Fibrosis

          -  Hospitalization for Pulmonary exacerbation

        Exclusion Criteria:

          -  Significant GI illness

          -  Participation in another Investigational Protocol

          -  Allergies to Doxycycline

          -  Sputum Culture only positive for Staphylococcus aureus,

          -  Pregnant or Nursing

          -  Unwilling to use effective birth control

          -  Elevated LFT's greater than 3x the upper limit of normal

          -  Creatinine greater than 1.5x the upper limit of normal

          -  Lung transplantation

          -  Substance abuse within 30 days of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Gaggar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <results_first_submitted>November 4, 2016</results_first_submitted>
  <results_first_submitted_qc>January 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <disposition_first_submitted>December 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>December 19, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 27, 2014</disposition_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Amit Gaggar</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo: placebo</description>
        </group>
        <group group_id="P2">
          <title>Doxycycline</title>
          <description>Doxycycline: 100 mg twice a day for 8 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo: placebo</description>
        </group>
        <group group_id="B2">
          <title>Doxycycline</title>
          <description>Doxycycline: 100 mg twice a day for 8 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="9.4"/>
                    <measurement group_id="B2" value="29.1" spread="8.9"/>
                    <measurement group_id="B3" value="28.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events</title>
        <description>Examines tolerability and safety with focus on adverse events (AEs) and serious adverse events (SAEs)</description>
        <time_frame>1 month from enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo: placebo
No SAEs noted in this group, 4 total AEs recorded.</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline</title>
            <description>Doxycycline: 100 mg twice a day for 8 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>Examines tolerability and safety with focus on adverse events (AEs) and serious adverse events (SAEs)</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Matrix Metalloprotease-9 (MMP-9) Protein Levels in Sputum</title>
        <description>Mean sputum matrix metalloprotease-9 (MMP-9) levels measured at the end of therapy</description>
        <time_frame>8 days past baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Doxycycline: 100 mg twice a day for 8 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo for 8 days</description>
          </group>
        </group_list>
        <measure>
          <title>Matrix Metalloprotease-9 (MMP-9) Protein Levels in Sputum</title>
          <description>Mean sputum matrix metalloprotease-9 (MMP-9) levels measured at the end of therapy</description>
          <units>ng/mg total protein</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4034" spread="3459"/>
                    <measurement group_id="O2" value="8837" spread="14752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.128</ci_lower_limit>
            <ci_upper_limit>0.633</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sputum Matrix Metalloprotease-9 (MMP-9) Activity End of Treatment</title>
        <description>Measurement of endogenous active matrix metalloprotease-9 (MMP-9) in the sputum</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo for 8 days</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline</title>
            <description>Doxycycline: 100 mg twice a day for 8 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sputum Matrix Metalloprotease-9 (MMP-9) Activity End of Treatment</title>
          <description>Measurement of endogenous active matrix metalloprotease-9 (MMP-9) in the sputum</description>
          <units>ng/mg total protein</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12683" spread="35275"/>
                    <measurement group_id="O2" value="3224" spread="2683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Pulmonary Function Over Treatment Duration</title>
        <description>Observe change in FEV1% predicted from beginning to end of study</description>
        <time_frame>Baseline to end of inpatient clinical exacerbation (average 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo for 8 days</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline</title>
            <description>Doxycycline: 100 mg twice a day for 8 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Pulmonary Function Over Treatment Duration</title>
          <description>Observe change in FEV1% predicted from beginning to end of study</description>
          <units>Percentage of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="10.4"/>
                    <measurement group_id="O2" value="10.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo: placebo</description>
        </group>
        <group group_id="E2">
          <title>Doxycycline</title>
          <description>Doxycycline: 100 mg twice a day for 8 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>tingling of lips</sub_title>
                <description>Self-limited tingling of lips</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <description>Transient pelvic pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Increased cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although the study has a relatively large number of subjects, this was a single center trial. In addition, it is possible that the protein readouts are mediated by modulating the dysregulated protease activity in the airway.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Amit Gaggar, MD</name_or_title>
      <organization>UAB</organization>
      <phone>934-5400</phone>
      <email>agaggar@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

